Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I attended the FAST meeting in Dublin this evening, CF hosted the meeting with presentations from AMRYT CEO and CFO, both went into great detail on how the plan was put together and how it all came about. CEO Joe Wiley presented for approx 40 mins on the current products and potential future lines including the potential for near term licensing deals on existing and currently in development products. By far the star of the show is Episalvan and its potential use in the sure of certain types of wounds. They explained the approvals they have to date and the timelines for further clinical trials. The level of detail, organisation and the ease with which they discussed the fairly complex subject matter was impressive along with calibre of the team particularly the BOD. The presentation will be on the FAST web, it is very interesting reading particularly the market cap comparisons of similar companies with drugs at various stages of regulatory approval. I was happy before I went in, I am a lot happier now.My personal view is that they see several significant events in the 3-15 month range post RTO.
Detractor
Not a extractor a realist! I own shares and I hope they succeed but I hate pumping
Hello son, If it's not a pharma start up, then what is it ? An aeroplane, is it ?
so what if it is ? (even though i disagree... its not a start up at all) the detractors should look at the founders of Shire..... Harry.... he and four mates started Shire from a shop in Hampshire. Now it's capped at £25b Those who had faith Harry's 'two bit' Shire ipo.... must counting their $s all the way to their bank
Don't be pumping...I own this as well.. Remember 4 mths ago we were an oil company so yes its a 2 bit start up
I thought we all waiting for April 19.. sp right at 3p mark.. Typical AIM
It will be a 50 ish mill cap with piers at same stage at 500 mill to a billion cap errr how do the funds make that cash again........
i might if i get the time.. btw i got a tip for the national Morning Assembly straight from the horses mouth
I dont think growth funds will be buying a 2 bit startup but its definately interesting
Cantillon: Fastnet chief explains switch to pharma http://www.irishtimes.com/business/health-pharma/cantillon-fastnet-chief-explains-switch-to-pharma-1.2598097 snippet : Why pharma? “Our feeling was that investing in a pharma company was one of the few market opportunities where a prospective investor might get the potential to generate a multiple uplift in share appreciation much like a successful oil exploration campaign can generate.” According to Friel, the Amryt team “believe they can transform Fastnet and potentially build it into one of Europe’s fastest growing orphan drug companies”. It has already acquired German pharma company, Birken and Sompharma in Switzerland. “Many of this peer group of companies with approved drugs already have market caps approaching a billion dollars, thus I feel confident that Fastnet is on the right track to success,” Friel gushed.
from tomorrow so some may wait till tomorrow to buy or or simply doing bed & breakfast. I have all mine in ISA as I am expecting good growth here.
I think no one really knows but my guess around that time they will give us more insight of their vision of the company. There could be influential investors in the capital raising. It's all up in the air and very dangerous not a place to put your retirement money into. If there is a market sell off it will probably trade in line so nothing is guaranteed. My 2 cents
Why exactly do you think it will open higher than 24p?
Might be broken today.. I'm looking at the European banks it doesn't look pretty.
Yes, If the books closed now, which I believe it is, then there are no 3p shares available to buy. Also I think the majority of these shares will be in sticky hands as a quick flip for 10% wouldn't be the smartest move imo Due a massive re-rate here in the coming months.
Birken may grab the headlines but let’s not forget Sompharma: this is a clever move by Amryt. Som has a second generation somatostatin analogue (SSA) for the treatment of acromegaly (and other diseases). It is a competitor to Novartis’ first generation Sandostatin (SSA) which has been around since the late 80s – it works in about 30% of patients but still generates $1Bn per year (it has been a Novartis top 10 blockbuster for many years). Novartis has since spent many hundreds of millions to make Signifor…it’s second gen version….this again only works in about 30% of patients but will give you diabetes in exchange (few clinicians are buying it plus it is very expensive). Som’s drug is more efficacious and is diabetes free…. Som/Amryt will be in the clinic early next year. If I was a Novartis Exec responsible for Signifor I’d be keeping a change of underwear ready in the desk draw when the clinical data comes out.
Would you buy above 3p if they will consolidate and open at 24p?
Harry Stratford - founder of FTSE 100 giant Shire Plc (LON:SHP), who set also set up ProStrakan. Shire being the world’s largest speciality pharma company. Joe Wiley - previously led the European office of life sciences venture capital firm Soffinova Ventures. Ray Stafford - was chairman, chief executive and majority shareholder of the Tosara Group, which owned, manufactured and marketed Sudocrem. Tosara was later sold to the American company Forest Laboratories, where he became executive vice president for global marketing. Michele Bellandi - former Head of Commercial for Europe at Shire. Find me a better BOD on AIM.
My shares here are firmly in the bottom drawer. Board of directors assembled just about the best you could possibly come across on AIM unlike 99% of shares on AIM I'm willing to trust this bunch to deliver massive shareholder returns in the short medium and long term. Find me another share on AIM that's has a drug that's has passed phase 3 trials and has been EU approved for marketing for a MC £50M. You wont because they are all over £500m-1bn. Get this this Phase 3 trial approved for treatment of EB (no other treatment on the market) and that's precisely the sort of valuation we will be looking at and this trial is expected to start in H2. As we already have Episalvan approved phase 3 for partial skin thickness wounds it is tipped to do very well in this next trial.
raise closed and over subscribed by a good bit so in theory all those selling last week to gain placing stock should finish. This to me is more like an IPO where shares commonly trade a high % above IPO price on day one as i suspect this will on the 19th.
Amryt Pharmaceuticals chief sees the potential in 'orphans' http://www.proactiveinvestors.com/companies/news/124271/amryt-pharmaceuticals-chief-sees-the-potential-in-orphans--124271.html